FOGLI, MIRIAM
 Distribuzione geografica
Continente #
NA - Nord America 872
EU - Europa 602
AS - Asia 165
AF - Africa 32
SA - Sud America 4
OC - Oceania 2
Totale 1.677
Nazione #
US - Stati Uniti d'America 870
GB - Regno Unito 192
SE - Svezia 106
IT - Italia 77
CN - Cina 69
DE - Germania 69
VN - Vietnam 37
IN - India 32
UA - Ucraina 31
FR - Francia 29
IE - Irlanda 27
CH - Svizzera 17
JO - Giordania 16
RU - Federazione Russa 16
TG - Togo 15
EE - Estonia 12
BG - Bulgaria 11
ZA - Sudafrica 11
BE - Belgio 7
JP - Giappone 5
FI - Finlandia 4
SC - Seychelles 4
BR - Brasile 3
IR - Iran 3
AU - Australia 2
HK - Hong Kong 2
AR - Argentina 1
CA - Canada 1
CI - Costa d'Avorio 1
LB - Libano 1
MX - Messico 1
NG - Nigeria 1
NL - Olanda 1
RO - Romania 1
RS - Serbia 1
SI - Slovenia 1
Totale 1.677
Città #
Southend 171
Fairfield 107
Chandler 101
Ashburn 80
Woodbridge 75
Seattle 67
Houston 56
Wilmington 51
Ann Arbor 50
Cambridge 39
Dong Ket 37
Princeton 33
Dublin 27
Jacksonville 18
Amman 16
Bern 15
Lomé 15
Padova 15
Turin 15
Westminster 15
Sofia 11
Nanjing 10
Beijing 8
Bologna 8
San Diego 8
Brussels 7
Berlin 6
Hebei 6
New York 6
Shenyang 6
Boardman 5
Bremen 5
Changsha 5
Jinan 5
Farra d'Isonzo 4
Helsinki 4
Jiaxing 4
Mahé 4
Medford 4
Mountain View 4
Tokyo 4
Washington 4
Milan 3
Mülheim 3
Nanchang 3
Negrar 3
Norwalk 3
Saint Petersburg 3
Taizhou 3
Verona 3
Zanjan 3
Zhengzhou 3
Bühl 2
Central District 2
Dearborn 2
Falls Church 2
Florence 2
Kuban 2
Kunming 2
Leawood 2
London 2
Los Angeles 2
Ningbo 2
Paris 2
San Francisco 2
São Paulo 2
Taiyuan 2
Tianjin 2
Abeokuta 1
Abidjan 1
Andover 1
Boydton 1
Buenos Aires 1
Canberra 1
Catanzaro 1
Changchun 1
Chicago 1
Costa Mesa 1
Easton 1
Frankfurt Am Main 1
Frankfurt am Main 1
Fuzhou 1
Groningen 1
Guangzhou 1
Hangzhou 1
Jerzu 1
Lausanne 1
Ljubljana 1
Madero 1
Melbourne 1
Modena 1
New Delhi 1
Parma 1
Plauen 1
Riva 1
Santiago 1
Toronto 1
Walnut 1
Totale 1.223
Nome #
Assessment of BCR-ABL1 Transcript Levels By Digital PCR (dPCR) in CML Patients who Achieved a Deep Molecular Response (DMR: MR4.0, MR4.5 And MR5.0) with Tkis May Improve the Detection of Minimal Residual Disease (MRD) and the Selection of Patients for Treatment Free Remission (TFR) 156
A population-based study of chronic myeloid leukemia patients treated with imatinib in first line 152
Effects of granulocyte colony stimulating-factor in a rat model of acute liver injury. 131
Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34- cell population with intrinsic resistance to imatinib. 130
NUCLEOFECTION IS AN EFFICIENT NON-VIRAL TRANSFECTION TECHNIQUE FOR HUMAN BONE MARROW-DERIVED MESENCHYMAL STEM CELLS. 130
The extracellular nucleotide UTP is a potent inducer of hematopoietic stem cell migration. 124
Extracellular nucleotides are potent stimulators of human hematopoietic stem cells in vitro and in vivo. 124
Managing chronic myeloid leukaemia in the elderly with intermittent imatinib treatment 98
Impact of comorbidities on the treatment of chronic myeloid leukemia with tyrosine-kinase inhibitors. 96
Mobilization of bone marrow-derived hematopoietic and endothelial stem cells after orthotopic liver transplantation and liver resection. 96
The kinetic status of hematopoietic stem cell subpopulations underlies a differential expression of genes involved in self-renewal, commitment, and engrftment. 94
Treating Ph+ Acute Lymphoblastic Leukemia (ALL) in the Elderly: The Sequence of Two Tyrosine Kinase Inhibitors (TKI) (Nilotinib and Imatinib) Does Not Prevent Mutations and Relapse. 87
Treating Ph+ Acute Lymphoblastic Leukemia (ALL) in the Elderly: The Sequence of Two Tyrosine Kinase Inhibitors (TKI) (Nilotinib and Imatinib) Does Not Prevent Mutations and Relapse 84
null 81
INTERMITTENT IMATINIB (INTERIM) TREATMENT IN PH+-CML ELDERLY PATIENTS IN STABLE COMPLETE CYTOGENETIC RESPONSE 75
Differences among young adults, adults and elderly chronic myeloid leukemia patients 52
Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation 13
In vitro anti-tumour activity of anti-CD80 and anti-CD86 immunotoxins containing type 1 ribosome-inactivating proteins 1
Totale 1.724
Categoria #
all - tutte 3.990
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.990


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201929 0 0 0 0 0 0 0 0 0 0 10 19
2019/2020508 68 17 4 33 59 52 60 64 61 34 23 33
2020/2021226 48 15 2 19 4 13 4 16 13 26 9 57
2021/2022321 14 9 15 42 26 22 3 23 15 35 65 52
2022/2023377 39 41 21 48 26 33 9 26 69 9 34 22
2023/2024104 6 12 12 15 10 26 6 7 1 4 5 0
Totale 1.724